| abstract |
This document discloses compounds that inhibit the kinase activity of a kinase containing a domain with two leucine zippers (DLK) (MAP3K12), pharmaceutical compositions and methods of treating diseases mediated by DLK, such as neurological diseases that result from traumatic injury neurons in the central nervous system and peripheral nervous system (eg, stroke, traumatic brain injury, spinal cord injury) or that result from a chronic neurodegenerative condition (eg, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis , spinal cerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy disease and other related conditions), which result from neuropathies resulting from neurological damage (peripheral neuropathy, induced chemotherapy, diabetic neuropathy and related conditions) and that result from cognitive impairment due to pharmacological effects (eg, chemotherapy-induced cognitive disorder, also known as "chemical brain"). |